New Drug Screening Platform Targets Neurological Disorders
Researchers have developed a drug screening platform that targets the primary cause of neurological and psychiatric disorders: protein expression levels. The platform uses the Protein Quantitation Ratioing (PQR) technique to monitor protein expression in human cell lines, employing CRISPR-Cas9 genome editing to insert the Protein Quantitation Reporter into target genes. This allows for high-throughput drug screening, measuring fluorescence as an assay. The platform aims to identify compounds that can correct protein synthesis malfunctions, which are responsible for many neurological conditions affecting over half the population. 
